Press release
Surging Autoimmune Diseases Propel Growth In Interleukin Biosimilars Market Emerges as a Core Driver of the Biosimilar Interleukins Market in 2025
biosimilar interleukins Market
What Is the Expected CAGR for the Biosimilar Interleukins Market Through 2025?
The market size of biosimilar interleukins has witnessed exponential growth in the past few years. It is projected to expand from $3.9 billion in 2024 to $5.41 billion in 2025, marking a compound annual growth rate (CAGR) of 39.0%. Factors contributing to this remarkable growth during the historical period include heightened incidence of autoimmune diseases, growing awareness about biosimilar interleukins, increased government backing for biosimilars, the broadening scope of the biosimilar market, and heightened demand for biosimilars among patients.
What's the Projected Size of the Global Biosimilar Interleukins Market by 2029?
Predictions suggest a robust expansion for the biosimilar interleukins market in the coming years, with an estimated rise to $20.79 billion by 2029, presenting a compound annual growth rate (CAGR) of 40.0%. The projected growth during this period is a reflection of factors like the expanding patient base, broader healthcare access, rising interest in personalized medicine, and an upward trend in minimally invasive procedures. The forecast period is also likely to witness pivotal developments in the realm of biosimilar technology, targeted immunotherapies, quality control and manufacturing sectors, allied with enhanced global collaboration.
View the full report here:
https://www.thebusinessresearchcompany.com/report/biosimilar-interleukin-global-market-report
Top Growth Drivers in the Biosimilar Interleukins Industry: What's Accelerating the Market?
The rise in autoimmune diseases like psoriasis and rheumatoid arthritis is anticipated to enhance the expansion of the interleukin biosimilars market in the projected timeline. Autoimmune disorders are situations where immune cells fail to differentiate between healthy cells and potentially harmful antibodies. Biopharmaceuticals such as anti-interleukin antibodies have demonstrated substantial clinical benefits in controlling the cells, guiding their proliferation, activation, and migration. For example, reports released by the National Institutes of Health (NIH), a biomedical research institution in the US, in February 2024, indicate that the annual global increases in incidence and prevalence of autoimmune diseases are estimated at 19.1% and 12.5% respectively. Hence, the escalating occurrence of autoimmune diseases is amplifying the demand for the biosimilar interleukins market, which is likely to propel the market growth.
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3433&type=smp
What Trends Will Shape the Biosimilar Interleukins Market Through 2029 and Beyond?
Key players in the biosimilar interleukins market are advancing their market position through the innovation of new offerings, such as Tofidence (tocilizumab-bavi). This product is a monoclonal antibody designed to attach to interleukin-6 receptors and has found use in treating a range of inflammatory autoimmune diseases. For example, in September 2023, Tofidence secured FDA approval as the inaugural biosimilar product referencing Genentech's Actemra (tocilizumab); this assertion comes following a successful application by the US biotech firm, Biogen. Administered via an intravenous infusion, Tofidence has been approved for use in the treatment of severe rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis.
What Are the Main Segments in the Biosimilar Interleukins Market?
The biosimilar interleukins market covered in this report is segmented -
1) By Type: IL-17, IL-23, IL-1, IL-5, IL-6
2) By Application: Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease (IBD), Other Applications
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Clinics, Research Institutes
Subsegments:
1) By IL-17: Autoimmune Disease Treatment, Inflammatory Disease Management
2) By IL-23: Psoriasis Treatment, Inflammatory Bowel Disease (IBD) Treatment
3) By IL-1: Rheumatoid Arthritis Management, Other Autoimmune Disorders
4) By IL-5: Asthma Treatment, Eosinophilic Disorders
5) By IL-6: Rheumatoid Arthritis Management, Inflammatory Disease Treatment
Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=3433&type=smp
Which Top Companies are Driving Growth in the Biosimilar Interleukins Market?
Major companies operating in the biosimilar interleukins market include Mabpharm Limitied, Gedeon Richter plc, Bio-Thera Solutions Ltd., Sunshine Guojian Pharmaceutical, Stada Arzneimittel AG, Teva Pharmaceutical Industries, 3SBio Inc., Shanghai Fosun Pharmaceuticals, Novartis AG, Pfizer Inc., Amgen Inc., F. Hoffmann-La Roche AG, Sanofi SA, Merck & Co. Inc., GlaxoSmithKline plc, Eli Lilly and Company, AstraZeneca plc, Qilu Pharmaceutical, Tonghua Dongbao, PROBIOMED S.A. de C.V., Biosidus S.A., LG Life Sciences, Viatris Inc.
Which Regions Will Dominate the Biosimilar Interleukins Market Through 2029?
The countries covered in the biosimilar interleukins market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3433
"This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work."
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Surging Autoimmune Diseases Propel Growth In Interleukin Biosimilars Market Emerges as a Core Driver of the Biosimilar Interleukins Market in 2025 here
News-ID: 4151079 • Views: …
More Releases from The Business Research Company
Segment Evaluation and Major Growth Areas in the Personalized Testing and Supple …
The personalized testing and supplements sector is gaining remarkable traction, driven by advancements in technology and a rising consumer focus on tailored health solutions. As more individuals seek customized wellness options, this market is set to experience substantial expansion in the coming years. Here's an in-depth look at its current valuation, key players, significant trends, and the main market segments shaping its future.
Market Valuation and Expansion Forecast for Personalized Testing…
Top Players and Market Competition in the Skin Microbiome Industry
The skin microbiome market is emerging as a significant area of interest due to growing awareness about the critical role of skin health and innovative skincare technologies. As research advances and consumer preferences shift towards more natural and science-backed products, this market is set to undergo substantial growth. Let's explore the current market size, key players, driving factors, and upcoming trends shaping the skin microbiome industry.
Projected Expansion in the Skin…
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market …
The upadacitinib market is poised for significant expansion over the coming years, driven by advances in treatment options and increasing awareness of autoimmune diseases. This report delves into the market's current size, key drivers, major players, and the emerging trends shaping its future trajectory.
Steady Growth Expected in Upadacitinib Market Size Through 2029
The market for upadacitinib is projected to reach $2.54 billion by 2029, growing at a robust compound annual…
Analysis of Key Market Segments Driving the Alzheimer's Disease Diagnostic Marke …
The Alzheimer's disease diagnostic sector is rapidly evolving as advancements in technology and healthcare infrastructure open new possibilities for early detection and personalized treatment. With rising awareness and innovative approaches, this market is poised for significant growth in the coming years. Let's explore the current market size, key drivers, leading companies, and emerging trends that are shaping this critical healthcare field.
Projected Market Size and Growth Trends in Alzheimer's Disease Diagnostics…
More Releases for Biosimilar
Interchangeable Biosimilar Humira Market Share Driven by Biologic Therapy Adopti …
Interchangeable Biosimilar Humira Market
The global market for Interchangeable Biosimilar Humira was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period
View sample report
https://reports.valuates.com/request/sample/QYRE-Auto-33I15005/Global_Interchangeable_Biosimilar_Humira_Market_Research_Report_2023
The Interchangeable Biosimilar Humira Market is experiencing significant market growth as healthcare providers and patients increasingly adopt biosimilar therapies for autoimmune and inflammatory conditions. Market trends indicate rising…
Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market?
In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial…
Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market?
In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial…
Biosimilar Market Treating More for Less: The Booming Infliximab Biosimilar Mark …
Infliximab Biosimilar Market worth $ XX Million by 2030 - Exclusive Report by InsightAce Analytic
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Infliximab Biosimilar Market- by Application (Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis and Others), End User (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Direct Distribution Channels), Trends, Industry Competition Analysis, Revenue and Forecast To 2030."
Get…
Biosimilar Monoclonal Antibodies Market
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " "Global Biosimilar Monoclonal Antibodies Market by Product (infliximab, trastuzumab, rituximab, adalimumab, bevacizumab, cetuximab, ranibizumab, denosumab, eculizumab, and other pipeline products), Indication (oncology, inflammatory & autoimmune disorders, chronic diseases, blood disorders, and other indications), Clinical Trial/Pipeline Analysis, Future Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
The Biosimilar Monoclonal Antibodies Market Size is valued at 5.02…
Infliximab Biosimilar Insight, 2022 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2022" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Interested to know more about the functioning of…
